Figure 1. Pharmacologic inhibition of GLI1/GLI2 results in decreased hTERT protein expression in human cancer cells.

A: HT29, SW480 (colon carcinoma cells), C4-2, DU145 and PC3 (prostate cancer cells) were treated for 72 hr with either DMSO (vehicle control) or GANT61 (20 µM). B: U87 (GBM cells) were treated with GANT61 (20 µM) for 0–72 hr. Steady state levels of GLI1, GLI2 and hTERT protein were determined by Western analysis. HSP90α/β was used as loading control.